<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134480">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879579</url>
  </required_header>
  <id_info>
    <org_study_id>S12-03713</org_study_id>
    <secondary_id>UL1TR000038</secondary_id>
    <nct_id>NCT01879579</nct_id>
  </id_info>
  <brief_title>Mobile Insulin Titration Intervention</brief_title>
  <acronym>MITI</acronym>
  <official_title>The Mobile Insulin Titration Intervention (MITI) Study: Innovative Chronic Disease Management of Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York City Health and Hospitals Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine whether text message (and phone)
      communication can be effectively utilized to adjust long-acting insulin, compared to
      standard practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current practice of insulin titration for diabetics requires multiple in-person clinic
      visits, during which a patient's long-acting insulin dose is adjusted until the optimal dose
      to control glycemia is reached. Finding this optimal dose can take weeks in an ideal
      setting, but often takes much longer in a busy urban clinic such as Bellevue Hospital
      Center. Relaying titration instructions to patients via phone and text message has the
      potential to decrease the titration timeline, thus reducing the number of clinic visits and
      the time it takes patients to reach their target blood glucose levels.

      For this pilot project, study staff will recruit patients who are initiating long-acting
      insulin treatment or initiating the titration of their existing long acting insulin
      treatment at Bellevue Hospital Center's Adult Primary Care Center. Patients who volunteer to
      enroll and provide informed consent will be randomized to one of two arms (MITI or current
      best practice arm) at the time of enrollment and stratified by whether the patient is
      initiating insulin treatment or initiating the titration of his/her existing insulin dose.
      The study staff will provide a cell phone (for temporary use) to any patients who are
      randomized to the MITI arm and don't own a personal cell phone (or whose personal cell phone
      is not able to receive the Sense Health text messages). Patients will use the cell phone
      free of cost to participate in the intervention (receive Sense Health text messages, send
      their fasting blood glucose levels, and speak with the diabetes nurse and study staff.)

      Patients in the MITI arm will receive automated text messages 5 weekdays per week, for up to
      12 weeks, from Sense Health. These text messages will request the patient's fasting blood
      glucose level. The patient will reply with his/her fasting blood glucose value, which will
      be logged in password-protected accounts on www.sensehealth.com. The clinic's diabetes
      nurses will check each patient's fasting blood glucose level on www.sensehealth.com each
      weekday and call any patient with fasting blood glucose values &lt; 80 mg/dL and &gt; 400 mg/dL.
      Each Thursday, patients will receive a phone call from a nurse, who will adjust the
      patient's insulin dose according to the study titration protocol. Each patient will continue
      to receive daily text messages and weekly phone calls until the first of three events occur:
      the patient reaches his/her optimal insulin dose for achieving glycemic control, 12 weeks
      elapse, or the patient withdraws from the study.

      Patients in the current best practice arm (CBP) will attend scheduled clinic appointments
      during which a provider will review the patient's fasting blood glucose log and titrate the
      insulin dose according to current best practice.

      Patients in both arms will continue receiving routine care, including HbA1c values every 3
      months and other routine labs and measures as per standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects who reach optimal long-acting insulin dose</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach optimal long-acting insulin dose</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time it takes a patient to reach his/her optimal long-acting insulin dose will be measured for both study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>baseline, approximately 3 months and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c will be measured at baseline, 3 months, and 6 months. Changes will be analyzed for both study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline treatment satisfaction</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Diabetes Treatment Satisfaction Questionnaire standard (DTSQs) will be used to measure the patient's satisfaction with diabetes treatment received prior to study participation. The questionnaire will be administered on the day of enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction after initiation of insulin titration</measure>
    <time_frame>approximately 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Diabetes Treatment Satisfaction Questionnaire standard (DTSQs) will be used to measure the patient's satisfaction with diabetes treatment received since initiation of long-acting insulin titration. The questionnaire will be administered at the time of 3 month appointment for HbA1c test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treatment satisfaction</measure>
    <time_frame>baseline and approximately 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) will be used to measure the change in the patient's satisfaction with his/her diabetes treatment since initiation of long-acting insulin titration. The questionnaire will be administered at the time of 3 month appointment for HbA1c test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of instances of hypoglycemia as indicated by fasting blood glucose levels or symptoms reported by patients in both study arms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of text message responses</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of text replies from patients will be compared to the total number of text messages sent requesting fasting blood glucose values. This outcome will be measured in the MITI arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of successful phone calls</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of phone conversations between the study staff and the patient compared to the number of attempts by the study staff to reach the patient by phone. This outcome will be measured in the MITI arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Healthcare Utilization</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of medication refill visits, clinic visits (not for insulin titration), and other visits at our hospital will be measured to compare healthcare utilization across study arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Costs</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Provider time spent on MITI vs. current best practice arm, titration visit information (number of in person titration visits, patient travel time, co-pay)  and patient healthcare utilization will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Qualitative patient satisfaction interview</measure>
    <time_frame>After patient reaches optimal insulin dose or at 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The study staff will interview MITI arm patients, using free-response questions, to assess their satisfaction with the intervention. The interviews will take place in person or over the phone at the patient's convenience, after the patient has reached his/her optimal insulin dose. If the patient does not reach optimal insulin dose, the interview will take place at approximately 12 weeks.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Mobile Insulin Titration Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current Best Practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mobile Insulin Titration Intervention</intervention_name>
    <description>Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.</description>
    <arm_group_label>Mobile Insulin Titration Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initiating long-acting insulin treatment or initiating the titration of long-acting
             insulin treatment

          -  Speaks English or Spanish

          -  Hemoglobin A1c &gt; or = 8%

          -  Able and willing to inject insulin

          -  Able and willing to provide informed consent

        Exclusion Criteria:

          -  Short-acting insulin treatment

          -  Systemic glucocorticoids

          -  Sustained elevated serum creatinine &gt; or = 1.5 mg/dL for men and &gt; or = 1.4 mg/dL for
             women

          -  Hypoglycemia unawareness

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Levy, MD</last_name>
    <phone>(212) 263-8924</phone>
    <email>Natalie.Levy@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adult Primary Care Clinic, Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Levy, MD</last_name>
      <phone>212-263-8924</phone>
      <email>Natalie.Levy@nyumc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 Nov;26(11):3080-6.</citation>
    <PMID>14578243</PMID>
  </reference>
  <reference>
    <citation>Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282-8.</citation>
    <PMID>15920040</PMID>
  </reference>
  <reference>
    <citation>Davies M, Lavalle-Gonz√°lez F, Storms F, Gomis R; AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab. 2008 May;10(5):387-99. Epub 2008 Mar 18.</citation>
    <PMID>18355327</PMID>
  </reference>
  <reference>
    <citation>Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009 Jun;11(6):623-31.</citation>
    <PMID>19515182</PMID>
  </reference>
  <reference>
    <citation>Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011 Jan;34(1):2-7. doi: 10.2337/dc10-1005.</citation>
    <PMID>21193619</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>June 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York University School of Medicine</investigator_affiliation>
    <investigator_full_name>Natalie Levy</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Telemedicine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
